Active Biotech AB (BTPC) Receives Tasquinimod Milestone Payment From Ipsen (IPN.PA) for 10TASQ10 Study
10/9/2013 9:41:56 AM
Active Biotech (NASDAQ OMX NORDIC:
ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Active
Biotech, under the terms of the co-development and commercialization agreement
on the novel candidate drug tasquinimod, has received a milestone payment of 12
million euros from Ipsen.
Help employers find you! Check out all the jobs and post your resume.
comments powered by